HDGC patients with germline CDH1 mutations have lower 1 and 5 years survival rates (36 and 4%, respectively) than HDGC patients without germline CDH1 mutations do (48 and 13%, respectively) (van der Post et al., 2015a), emphasizing the importance of screening for CDH1 germline mutations (Benusiglio et al., 2015). This evidence concerns the gene CDH1 and Familial gastric cancer.